文献速递胸部肿瘤

阿来替尼治疗ALK阳性非小细胞肺癌的关键II期研究(NP28673和NP28761)的汇总全身疗效与安全性数据

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-07-06

汇总两项II期研究(NP28673和NP28761)共225例ALK阳性NSCLC患者,接受阿来替尼600mg每日两次口服。在可评估疗效的189例患者中,独立评审委员会评估的客观缓解率为51.3%,中位缓解持续时间14.9个月,中位无进展生存期8.3个月,中位总生存期26.0个月。汇总分析证实了阿来替尼稳健的全身疗效和可接受的安全性。

要点

  • 阿来替尼600mg每日两次在ALK阳性NSCLC中客观缓解率达51.3%。
  • 中位缓解持续时间14.9个月,中位无进展生存期8.3个月。
  • 3级及以上不良事件发生率为40%,6%的患者因不良事件停药。

核心结论

  • 汇总数据分析证实阿来替尼在ALK阳性NSCLC中具有稳健的全身疗效和持久缓解率,且安全性可接受。

研究设计与样本

  • 两项II期研究(NP28761和NP28673)的汇总分析,纳入225例ALK阳性NSCLC患者,其中NP28673组138例,NP28761组87例。
  • 患者为克唑替尼治疗期间进展或不能耐受克唑替尼者,接受阿来替尼600mg每日两次口服。

主要发现

  • 可评估疗效人群189例(84%),其中NP28673组122例,NP28761组67例。
  • 独立评审委员会评估的客观缓解率为51.3%(95%CI:44.0-58.6),均为部分缓解。
  • 疾病控制率为78.8%(95%CI:72.3-84.4),中位缓解持续时间为14.9个月(95%CI:11.1-20.4),事件发生率为58%。
  • 中位无进展生存期为8.3个月(95%CI:7.0-11.3),中位总生存期为26.0个月(95%CI:21.4-不可估计)。
  • 3级及以上不良事件发生率为40%,6%的患者因不良事件退出治疗,33%的患者因不良事件导致剂量中断或调整。

关键数值与推荐

  • 客观缓解率51.3%(95%CI:44.0-58.6),疾病控制率78.8%(95%CI:72.3-84.4)。
  • 中位缓解持续时间14.9个月(95%CI:11.1-20.4),中位无进展生存期8.3个月(95%CI:7.0-11.3),中位总生存期26.0个月(95%CI:21.4-不可估计)。
  • 3级及以上不良事件发生率40%,因不良事件退出治疗率6%,因不良事件导致剂量中断或调整率33%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses. METHODS: Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib. Patients received oral alectinib, 600 mg twice daily. The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety. RESULTS: The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761). The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]). In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0-58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3-84.4), and the median duration of response was 14.9 months (95% CI: 11.1-20.4) after 58% of events. Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0-11.3) and median overall survival was 26.0 months (95% CI: 21.4-not estimable). Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification. CONCLUSIONS: This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate. Alectinib also had an acceptable safety profile with a longer duration of follow-up.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JC, Ou SI, De Petris L, et al. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28689043. doi:10.1016/j.jtho.2017.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。